Protara Therapeutics, Inc.
$5.3
▲
1.39%
2026-04-21 09:43:01
www.protaratx.com
NGM: TARA
Explore Protara Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$286.65 M
Current Price
$5.3
52W High / Low
$7.82 / $2.77
Stock P/E
—
Book Value
$3.67
Dividend Yield
—
ROCE
-32.51%
ROE
-31.6%
Face Value
—
EPS
$-1.34
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
46
Beta
1.5
Debt / Equity
1.71
Current Ratio
14.58
Quick Ratio
14.58
Forward P/E
-3.57
Price / Sales
—
Enterprise Value
$116.06 M
EV / EBITDA
-1.81
EV / Revenue
—
Rating
Strong Buy
Target Price
$25.71
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Silence Therapeutics plc | $7.93 | — | $349.74 M | — | -76.17% | -90.27% | $2.6 / $0.5 | $1.32 |
| 2. | Halozyme Therapeutics, Inc. | $68.8 | 26.89 | $8.18 B | — | 34.18% | 1.54% | $82.22 / $47.5 | $0.41 |
| 3. | Longeveron Inc. | $1.04 | — | $25.59 M | — | -377.18% | -1.65% | $1.83 / $0.47 | $0.25 |
| 4. | AgomAb Therapeutics NV | $10.79 | — | $0.28 M | — | -24.35% | -27.25% | $17.45 / $9 | $-7,123.4 |
| 5. | Sutro Biopharma, Inc. | $34.58 | — | $572.9 M | — | -106.34% | 435.02% | $34.58 / $5.23 | $-15.43 |
| 6. | TG Therapeutics, Inc. | $36.96 | 12.6 | $5.64 B | — | 13.56% | 1.03% | $46.48 / $25.28 | $4.52 |
| 7. | Zevra Therapeutics, Inc. | $10.78 | 7.23 | $601.51 M | — | -1.72% | 85.66% | $13.16 / $6.85 | $2.72 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -19.08 M | -14.76 M | -16.59 M | -14.12 M | -14.31 M |
| Net Profit | -17.31 M | -13.26 M | -14.96 M | -11.91 M | -12.77 M |
| EPS in Rs | -0.32 | -0.25 | -0.28 | -0.22 | -0.24 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -64.55 M | -49.15 M | -43.61 M | -37.55 M |
| Net Profit | -57.44 M | -44.6 M | -40.42 M | -65.95 M |
| EPS in Rs | -1.06 | -0.82 | -0.75 | -1.22 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 209.47 M | 181.45 M | 78.95 M | 113.29 M |
| Total Liabilities | 13.06 M | 14.32 M | 10.63 M | 11.21 M |
| Equity | 196.41 M | 167.13 M | 68.32 M | 102.08 M |
| Current Assets | 159.5 M | 172.16 M | 68.7 M | 86.15 M |
| Current Liabilities | 10.94 M | 10.96 M | 6.15 M | 5.74 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -56.37 M | -35.81 M | -37.56 M | -26.46 M |
| Investing CF | -139.49 M | 19.16 M | 53.11 M | 14.95 M |
| Financing CF | 82.72 M | 139.87 M | -0.09 M | -0.09 M |
| Free CF | -56.46 M | -35.87 M | -37.6 M | -26.58 M |
| Capex | -0.09 M | -0.06 M | -0.04 M | -0.12 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -10.33% | 38.71% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.